CD271+ Bone Marrow Mesenchymal Stem Cells May Provide a Niche for Dormant Mycobacterium tuberculosis

B Das, SS Kashino, I Pulu, D Kalita, V Swami… - Science translational …, 2013 - science.org
B Das, SS Kashino, I Pulu, D Kalita, V Swami, H Yeger, DW Felsher, A Campos-Neto
Science translational medicine, 2013science.org
Mycobacterium tuberculosis (Mtb) can persist in hostile intracellular microenvironments
evading immune cells and drug treatment. However, the protective cellular niches where
Mtb persists remain unclear. We report that Mtb may maintain long-term intracellular viability
in a human bone marrow (BM)–derived CD271+/CD45− mesenchymal stem cell (BM-MSC)
population in vitro. We also report that Mtb resides in an equivalent population of BM-MSCs
in a mouse model of dormant tuberculosis infection. Viable Mtb was detected in …
Mycobacterium tuberculosis (Mtb) can persist in hostile intracellular microenvironments evading immune cells and drug treatment. However, the protective cellular niches where Mtb persists remain unclear. We report that Mtb may maintain long-term intracellular viability in a human bone marrow (BM)–derived CD271+/CD45 mesenchymal stem cell (BM-MSC) population in vitro. We also report that Mtb resides in an equivalent population of BM-MSCs in a mouse model of dormant tuberculosis infection. Viable Mtb was detected in CD271+/CD45 BM-MSCs isolated from individuals who had successfully completed months of anti-Mtb drug treatment. These results suggest that CD271+ BM-MSCs may provide a long-term protective intracellular niche in the host in which dormant Mtb can reside.
AAAS